These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
676 related items for PubMed ID: 33935098
1. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People. de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG. J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098 [Abstract] [Full Text] [Related]
4. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW. Alzheimers Res Ther; 2019 Oct 10; 11(1):83. PubMed ID: 31601267 [Abstract] [Full Text] [Related]
6. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic. Shea YF, Ha J, Chu LW. Psychogeriatrics; 2015 Dec 10; 15(4):235-41. PubMed ID: 25533477 [Abstract] [Full Text] [Related]
11. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease. Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T. J Neurol Neurosurg Psychiatry; 2010 Jun 10; 81(6):608-10. PubMed ID: 20522869 [Abstract] [Full Text] [Related]
12. Neuropsychiatric symptoms and α-Synuclein profile of patients with Parkinson's disease dementia, dementia with Lewy bodies and Alzheimer's disease. Bougea A, Stefanis L, Paraskevas GP, Emmanouilidou E, Efthymiopoulou E, Vekrelis K, Kapaki E. J Neurol; 2018 Oct 10; 265(10):2295-2301. PubMed ID: 30083953 [Abstract] [Full Text] [Related]
16. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. van Steenoven I, Majbour NK, Vaikath NN, Berendse HW, van der Flier WM, van de Berg WDJ, Teunissen CE, Lemstra AW, El-Agnaf OMA. Mov Disord; 2018 Nov 10; 33(11):1724-1733. PubMed ID: 30440090 [Abstract] [Full Text] [Related]
18. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies. Bolsewig K, van Unnik AAJM, Blujdea ER, Gonzalez MC, Ashton NJ, Aarsland D, Zetterberg H, Padovani A, Bonanni L, Mollenhauer B, Schade S, Vandenberghe R, Poesen K, Kramberger MG, Paquet C, Bousiges O, Cretin B, Willemse EAJ, Teunissen CE, Lemstra AW, European-Dementia With Lewy Bodies (E-DLB) ConsortiumFrom the Department of Laboratory Medicine (K.B., E.R.B., E.A.J.W., C.E.T.) and Alzheimer Center Amsterdam (A.A.J.M.U., A.W.L.), Amsterdam UMC, the Netherlands; Department of Quality and Health Technology (M.C.G.), University of Stavanger; The Norwegian Centre for Movement Disorders (M.C.G.) and the Centre for Age-Related Medicine (M.C.G., N.J.A., D.A.), Stavanger University Hospital, Norway; Department of Psychiatry and Neurochemistry (N.J.A., H.Z.), the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Old Age Psychiatry (N.J.A., D.A.), King's College London, United Kingdom; Clinical Neurochemistry Laboratory (H.Z.), Sahlgrenska University Hospital, Mölndal, Sweden; Department of Neurodegenerative Disease (H.Z.), UCL Institute of Neurology; UK Dementia Research Institute at UCL (H.Z.), London, United Kingdom; Hong Kong Center for Neurodegenerative Diseases (H.Z.), Hong Kong, China; Wisconsin Alzheimer's Disease Research Center (H.Z.), University of Wisconsin School of Medicine and Public Health, Madison; Neurology Unit (A.P.), Department of Clinical and Experimental Sciences, University of Brescia, Italy; Department of Medicine and Aging Sciences (L.B.), University G. d'Annunzio of Chieti-Pescara, Chieti, Italy; Department of Neurology (B.M.), University Medical Center Göttingen; Paracelsus-Elena-Klinik (B.M., S.S.), Germany; Department of Neurosciences (R.V., K.P.), KU Leuven, Belgium; Department of Neurology and Medical Faculty (M.G.K.), University Medical Center Ljubljana, Slovenia; Department of Neurobiology (M.G.K.), Karolinska Institutet, Huddinge, Sweden; Université de Paris Cité (C.P.), Centre de Neurologie Cognitive, Paris; Laboratory of Biochemistry and Molecular Biology (O.B.), University Hospital of Strasbourg; University of Strasbourg and CNRS (O.B., B.C.); Memory Resource and Research Centre (B.C.), University Hospital of Strasbourg, France; Department of Neurology (E.A.J.W.), Multiple Sclerosis Center; Research Center for Clinical Neuroimmunology and Neuroscience Basel (E.A.J.W.); and Departments of Biomedicine and Clinical Research (E.A.J.W.), University Hospital Basel and University of Basel, Switzerland.. Neurology; 2024 Jun 25; 102(12):e209418. PubMed ID: 38830138 [Abstract] [Full Text] [Related]